Numeta G13e

A mixture of essential and non‑essential amino acids, the active ingredient in Numeta G13e, is an amino acid solution presented as a parenteral formulation for intravenous use. It supplies balanced amino acid nutrition to patients who cannot receive enteral feeding, such as critically ill, postoperative or neonatal patients.

GNH USA supplies Numeta G13e as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Numeta G13e is used in parenteral nutrition to provide essential amino acids for patients unable to receive oral or enteral feeding. Critical illness: supports protein synthesis and nitrogen balance in critically ill patients. Post‑operative care: aids recovery by supplying amino acids after major surgery. Neonatal nutrition: provides balanced amino acid profile for preterm or low‑birth‑weight infants. Renal or hepatic impairment: offers tailored amino acid composition for patients with organ dysfunction.

Intravenous amino acid solutions may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hyperglycaemia: elevated blood glucose levels, especially in diabetic patients. - Electrolyte disturbances: shifts in potassium, phosphate or magnesium. - Mild infusion site reactions: erythema, warmth or discomfort at the catheter site. - Increased serum urea: transient rise due to amino acid catabolism. - Fluid overload: signs of edema or pulmonary congestion in volume‑sensitive patients.

Serious or Rare Side Effects: - Allergic reaction: urticaria, bronchospasm or anaphylaxis requiring immediate treatment. - Metabolic acidosis: significant drop in blood pH due to excess amino acid metabolism. - Hepatic dysfunction: abnormal liver enzymes in patients with pre‑existing liver disease. - Hyperammonemia: elevated ammonia levels, particularly in severe liver impairment.

When prescribing Numeta G13e, clinicians should observe several precautionary measures to ensure safe administration. - Patient assessment: evaluate renal, hepatic and metabolic status before initiation. - Monitoring: regularly check blood glucose, electrolytes and nitrogen balance during therapy. - Infusion rate: administer according to recommended speed to avoid circulatory overload. - Compatibility: verify compatibility with other intravenous solutions and medications. - Pregnancy and lactation: use only if benefits outweigh potential risks; limited data available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Amino acid solutions can interact with certain drugs and clinical conditions, necessitating awareness of potential interactions.

Major Interactions (Avoid): - High‑dose insulin: concurrent use may cause severe hypoglycaemia. - Loop diuretics: may exacerbate electrolyte imbalances, especially potassium loss. - Acidifying agents: can increase risk of metabolic acidosis when combined.

Moderate Interactions (Monitor Closely): - Corticosteroids: may increase protein catabolism, requiring dosage adjustment. - Anticonvulsants (e.g., phenobarbital): may alter amino acid metabolism. - Renal replacement therapy: may necessitate modified dosing or monitoring. - Parenteral lipid emulsions: co‑administration requires careful monitoring of caloric load.